Focus: Dyne Therapeutics is a publicly traded biotech focused on antibody-oligonucleotide conjugate treatments for rare muscle diseases, operating at mid-cap scale with 201-500 employees.
Profile data last refreshed 56m ago · AI intelligence enriched 2w ago
Cooling — net -7 jobs in 30d
14 added, 21 removed. Slower than typical.
Best suited for scientists and early-career professionals willing to accept pre-commercialization risk in exchange for exposure to a novel modality and rare disease impact.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dyne Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dyne Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles